The new investments will expand manufacturing sites in Maryland, Texas and California. But AstraZeneca shares have fallen nearly 6% this year, underperforming a near 9% rise in the wider European ...
AstraZeneca said on Tuesday it would invest US$3.5 billion of capital in the US focused on expanding its research and manufacturing footprint by the end of 2026. Some US$2 billion of that investment, ...
AstraZeneca's Q3 sales rose 18% YoY to $ ... The new investments will expand manufacturing sites in Maryland, Texas, and California and create 1,000 high-skilled jobs. “Our multibillion-dollar ...
AstraZeneca has announced a major expansion ... spend $2bn to bolster its manufacturing capacity in states including Maryland and Texas as well as on the west coast. This would bring its total ...
(Reuters) -Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time ... The new investments will expand manufacturing sites in Maryland, Texas and California and create ...
AstraZeneca made headlines for several reasons on Tuesday ... The investment will also support creation of a new next generation manufacturing facility, focused on biologics, in Maryland as well as ...
(Reuters) -Drugmaker AstraZeneca lifted its annual sales and ... The new investments will expand manufacturing sites in Maryland, Texas and California and create 1,000 high-skilled jobs in the ...
AstraZeneca’s expanding footprint in the ... Massachusetts A next generation manufacturing facility for biologics in Maryland Cell therapy manufacturing capacity on the West and East Coasts ...
AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts A next generation manufacturing facility for biologics in ...
many of the projects AstraZeneca outlined are, in fact, not exactly new. For instance, the company announced plans for its cell therapy facility in Rockville, Maryland back in February.